Vivek Subbiah: Incredible meeting of the Early Phase Drug Development minds
Vivek Subbiah shared on LinkedIn:
“Wow! Incredible meeting of the Early Phase Drug Development minds. Exhilarating discussions on what’s next in oncology with the amazing Dr. Johanna Bendell and team from Roche and our terrific Marcy Vallone Sarah Cannon Research Institute!
We need some direct flights from Nashville to Europe!”
Source: Vivek Subbiah/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023